This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Grifols Announces Robust Inventory Of HyperRAB® S/D Rabies Immune Globulin For Treatment Of Rabies Exposure

RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2012 /PRNewswire/ -- Grifols, a global healthcare company that produces medicines derived from human plasma, announced today it has a robust inventory of HyperRAB® S/D (rabies immune globulin [human]) to overcome U.S. supply constraints caused by an increase in rabies exposures during 2012. HyperRAB® S/D provides immediate immune protection to patients who are exposed to rabies but have not yet been vaccinated against the deadly virus.

(Logo: )

The Centers for Disease Control and Prevention (CDC) confirmed in a September 19 announcement that Grifols' HyperRAB® S/D is the only immune globulin available in sufficient quantities to meet the market demand for rabies post-exposure prophylaxis – the recommended protocol to prevent rabies infection following exposure to the virus. Post-exposure prophylaxis consists of treatment with rabies immune globulin to provide rapid, temporary immunity against the virus followed by a series of rabies vaccines to generate permanent immunity.

According to the CDC, rabies infections among animals have increased in the past year as a result of a warm summer and a mild 2011 winter, with higher reported incidences of rabies among raccoons, skunks, foxes, beavers, and bats and an earlier start to the bat season.

No human cases of rabies infection have been reported in the U.S. in 2012, but the number of human exposures to rabid animals appears higher this year. On a typical summer day, up to 100 cases of potential contacts with a rabid animal are reported across the nation.  There were six cases of human rabies infections reported in 2011 – exceeding the typical annual numbers of only one or two.

Grifols is committed to maintaining its supply of HyperRAB® S/D to meet the needs of patients who are potentially exposed to rabies. CDC guidelines recommend administering rabies immune globulin in conjunction with a patient's first rabies vaccination to ensure immediate protection against the rabies virus until the vaccine can mount a permanent defense.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs